Vigil Neuroscience Dividend

Dividend criteria checks 0/6

Vigil Neuroscience does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$2.20
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Feb 01

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Oct 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Jun 27

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Mar 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Nov 29

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if VIGL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VIGL's dividend payments have been increasing.

Dividend Yield vs Market

Vigil Neuroscience Dividend Yield vs Market

How does VIGL dividend yield compare to the market?
Segment	Dividend Yield
Company (VIGL)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (VIGL)	n/a

Notable Dividend: Unable to evaluate VIGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VIGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate VIGL's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VIGL has not reported any payouts.

Vigil Neuroscience Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

New major risk - Revenue and earnings growth

Price target increased by 8.4% to US$18.57

New minor risk - Market cap size

Vigil Neuroscience, Inc., Annual General Meeting, Jun 05, 2024

Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting

New minor risk - Shareholder dilution

Price target increased by 10% to US$18.86

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces Executive Changes

New minor risk - Market cap size

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

New minor risk - Market cap size

Price target decreased by 14% to US$17.13

Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927

Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP

Vigil Neuroscience, Inc. Presents VGL101 Complete Phase 1 Data and Phase 2 Ignite Trial Design at the 2023 American Neurological Association Annual Meeting

New major risk - Share price stability

Vigil Neuroscience, Inc. Appoints Christopher J. Silber, M.D. as Chief Medical Officer

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Appoints Samantha Budd Haeberlein to Its Board of Directors

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Announces Resignation of Shaan Gandhi, from Member of Board of Directors

High number of new and inexperienced directors

Vigil Neuroscience, Inc. Announces Executive Changes

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Chief Medical Officer notifies of intention to sell stock

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

Vigil draws bullish view at Wedbush on upcoming readout for lead asset

Vigil Neuroscience, Inc. announced that it has received $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience, Inc. announced that it expects to receive $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience announces $75M PIPE financing

Vigil Neuroscience Appoints Suzanne Bruhn to Its Board of Directors

We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2000 Growth Index

Vigil Neuroscience, Inc. Expands VGL101 Phase 1 Trial to Australia

Vigil Neuroscience, Inc. Appoints Christopher Verni as General Counsel and Mary Thistle to Its Board of Directors

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?

Vigil Neuroscience, Inc. has completed an IPO in the amount of $98 million.

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies